항혈소판제 시장 : 약제 유형, 제형, 적응증, 작용기서, 투여 방법, 유통 채널, 최종사용자별 - 세계 예측(2025-2030년)

The Antiplatelet Market was valued at USD 3.93 billion in 2023, expected to reach USD 4.19 billion in 2024, and is projected to grow at a CAGR of 6.67%, to USD 6.19 billion by 2030.

Antiplatelet drugs are essential therapeutics used to prevent platelet aggregation, thereby mitigating the risk of thrombotic events such as stroke and myocardial infarction. The necessity for such drugs is underscored by the global increase in cardiovascular diseases, driven by aging populations, dietary habits, and sedentary lifestyles. These medications find primary application in acute coronary syndrome, after percutaneous coronary intervention, and in the prevention of ischemic strokes. The end-use scope predominantly includes hospitals, clinics, and ambulatory surgical centers, signifying a strong demand in regions with advanced healthcare infrastructure as well as emerging markets experiencing rapid healthcare enhancements. Key growth factors of this market include rising cardiovascular disease burden, increased awareness and diagnosis rates, and the development of novel drugs with improved efficacy and safety profiles. There are significant opportunities linked with the introduction of personalized medicine approaches and the continued development of combination therapies, which offer enhanced clinical outcomes.

Despite its potential, the antiplatelet market faces several limitations and challenges. Stringent regulatory requirements, potential side effects, and the high cost of advanced therapeutics can hinder market growth. Additionally, the availability of alternative therapies like anticoagulants may impact antiplatelet drug adoption. Nevertheless, innovative research areas such as the development of new drug delivery systems, and improved formulations with fewer side effects, present significant business growth opportunities. Investing in precision medicine and biotechnology for personalized treatment options can also be pivotal. Meanwhile, understanding the competitive dynamics, such as consolidation trends among pharmaceutical companies and strategic collaborations for research and development, is crucial for market penetration and expansion. A precise focus on addressing these challenges, aligning with regulatory norms, and leveraging technological advancements will be critical in navigating the future landscape of the antiplatelet market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antiplatelet Market

The Antiplatelet Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing global prevalence of cardiovascular diseases
  • Supportive government investment in the pharmaceutical sector
• Market Restraints
  • Rising incidences of the product recalls for antiplatelets
  • Side effects and risk of bleeding associated with antiplatelet
• Market Opportunities
  • Growing trend toward personalized medicine to develop personalized antiplatelet therapies
  • Extensive research & development and clinical trials of novel antiplatelet drugs
• Market Challenges
  • Stringent regulatory requirements and the lengthy approval process for new drugs

Porter's Five Forces: A Strategic Tool for Navigating the Antiplatelet Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antiplatelet Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antiplatelet Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antiplatelet Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antiplatelet Market

A detailed market share analysis in the Antiplatelet Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antiplatelet Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antiplatelet Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antiplatelet Market

A strategic analysis of the Antiplatelet Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antiplatelet Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alta Laboratories Ltd., Apotex Inc., AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Bristol Laboratories Ltd., Bristol-Myers Squibb Company, Cipla Limited, Daiichi Sankyo Company, Limited, Dr. Reddy's Laboratories Ltd., Genentech, Inc. by F. Hoffmann-La Roche AG, Lupin Ltd., Natco Pharma Limited, Otsuka Pharmaceutical Co., Ltd., Perrigo Company PLC, Pfizer Inc., Sanofi S.A, Shenzhen Salubris Pharmaceuticals Co., Ltd., and Sun Pharmaceutical Industries, Inc..

Market Segmentation & Coverage

This research report categorizes the Antiplatelet Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Type, market is studied across Abciximab, Aspirin, Clopidogrel, Dipyridamole, Prasugrel, Ticagrelor, Ticlopidine, and Tirofiban.
• Based on Drug Formulation, market is studied across Capsule, Injection, and Tablet.
• Based on Indication, market is studied across Coronary Artery Disease, Peripheral Artery Disease, and Stroke. The Stroke is further studied across Hemorrhagic and Ischemic.
• Based on Mechanism of Action, market is studied across COX Inhibitors, P2Y12 Inhibitors, and Phosphodiesterase Inhibitors.
• Based on Mode of Administration, market is studied across Intravenous and Oral.
• Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
• Based on End User, market is studied across Ambulatory Surgical Centers, Clinics, Homecare Settings, and Hospitals.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, Michigan, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing global prevalence of cardiovascular diseases
    • 5.1.1.2. Supportive government investment in the pharmaceutical sector
  • 5.1.2. Restraints
    • 5.1.2.1. Rising incidences of the product recalls for antiplatelets
    • 5.1.2.2. Side effects and risk of bleeding associated with antiplatelet
  • 5.1.3. Opportunities
    • 5.1.3.1. Growing trend toward personalized medicine to develop personalized antiplatelet therapies
    • 5.1.3.2. Extensive research & development and clinical trials of novel antiplatelet drugs
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulatory requirements and the lengthy approval process for new drugs
• 5.2. Market Segmentation Analysis
  • 5.2.1. Drug Formulation: Expanding use of injection for antiplatelet usage
  • 5.2.2. Drug Type : Extensive use of Abciximab for high-risk cardiovascular interventions
  • 5.2.3. Mechanism of Action: Burgeoning utilization of COX inhibitors for inhibiting the blockages
  • 5.2.4. Indication: Growing demand for antiplatelet medications addressing the rising prevalence of cardiovascular diseases
  • 5.2.5. Mode of Administration: Proliferating use of oral routes for administration of antiplatelets
  • 5.2.6. End User : Growing need of antiplatelet medications in ambulatory surgical centers
  • 5.2.7. Distribution Channel : Extensive use of hospital pharmacies owing to their direct access to patients
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Antiplatelet Market, by Drug Type

• 6.1. Introduction
• 6.2. Abciximab
• 6.3. Aspirin
• 6.4. Clopidogrel
• 6.5. Dipyridamole
• 6.6. Prasugrel
• 6.7. Ticagrelor
• 6.8. Ticlopidine
• 6.9. Tirofiban

7. Antiplatelet Market, by Drug Formulation

• 7.1. Introduction
• 7.2. Capsule
• 7.3. Injection
• 7.4. Tablet

8. Antiplatelet Market, by Indication

• 8.1. Introduction
• 8.2. Coronary Artery Disease
• 8.3. Peripheral Artery Disease
• 8.4. Stroke
  • 8.4.1. Hemorrhagic
  • 8.4.2. Ischemic

9. Antiplatelet Market, by Mechanism of Action

• 9.1. Introduction
• 9.2. COX Inhibitors
• 9.3. P2Y12 Inhibitors
• 9.4. Phosphodiesterase Inhibitors

10. Antiplatelet Market, by Mode of Administration

• 10.1. Introduction
• 10.2. Intravenous
• 10.3. Oral

11. Antiplatelet Market, by Distribution Channel

• 11.1. Introduction
• 11.2. Hospital Pharmacies
• 11.3. Online Pharmacies
• 11.4. Retail Pharmacies

12. Antiplatelet Market, by End User

• 12.1. Introduction
• 12.2. Ambulatory Surgical Centers
• 12.3. Clinics
• 12.4. Homecare Settings
• 12.5. Hospitals

13. Americas Antiplatelet Market

• 13.1. Introduction
• 13.2. Argentina
• 13.3. Brazil
• 13.4. Canada
• 13.5. Mexico
• 13.6. United States

14. Asia-Pacific Antiplatelet Market

• 14.1. Introduction
• 14.2. Australia
• 14.3. China
• 14.4. India
• 14.5. Indonesia
• 14.6. Japan
• 14.7. Malaysia
• 14.8. Philippines
• 14.9. Singapore
• 14.10. South Korea
• 14.11. Taiwan
• 14.12. Thailand
• 14.13. Vietnam

15. Europe, Middle East & Africa Antiplatelet Market

• 15.1. Introduction
• 15.2. Denmark
• 15.3. Egypt
• 15.4. Finland
• 15.5. France
• 15.6. Germany
• 15.7. Israel
• 15.8. Italy
• 15.9. Netherlands
• 15.10. Nigeria
• 15.11. Norway
• 15.12. Poland
• 15.13. Qatar
• 15.14. Russia
• 15.15. Saudi Arabia
• 15.16. South Africa
• 15.17. Spain
• 15.18. Sweden
• 15.19. Switzerland
• 15.20. Turkey
• 15.21. United Arab Emirates
• 15.22. United Kingdom

16. Competitive Landscape

• 16.1. Market Share Analysis, 2023
• 16.2. FPNV Positioning Matrix, 2023
• 16.3. Competitive Scenario Analysis
  • 16.3.1. Diapin Therapeutics advances innovative antiplatelet therapy DT678 with FDA feedback
  • 16.3.2. FDA fast-tracks approval of bentracimab as the first breakthrough solution for ticagrelor reversal
  • 16.3.3. Eugia US recalled 15 500 single-dose vials of eptifibatide injection
  • 16.3.4. Avenacy enters U.S. market with launch of generic eptifibatide injection, targeting ACS and PCI treatment
  • 16.3.5. UCHealth pioneers genetic screening for Clopidogrel to enhance heart health outcomes and revolutionize personalized medicine
  • 16.3.6. Ascendia Pharmaceuticals and AcuteBio unveil innovative IV nanoemulsion clopidogrel to optimize coronary artery disease treatment with FDA IND approval
  • 16.3.7. SERB Pharmaceuticals and SFJ Pharmaceuticals announced a U.S. partnership for bentracimab, a ticagrelor reversal agent
  • 16.3.8. Bristol Myers Squibb-Janssen collaboration advances FXIa inhibitors with clinical trials
• 16.4. Strategy Analysis & Recommendation
  • 16.4.1. Pfizer Inc.
  • 16.4.2. Bayer AG
  • 16.4.3. AstraZeneca PLC
  • 16.4.4. Sanofi S.A

Companies Mentioned

• 1. Abbott Laboratories
• 2. Alta Laboratories Ltd.
• 3. Apotex Inc.
• 4. AstraZeneca PLC
• 5. Bayer AG
• 6. Boehringer Ingelheim International GmbH
• 7. Bristol Laboratories Ltd.
• 8. Bristol-Myers Squibb Company
• 9. Cipla Limited
• 10. Daiichi Sankyo Company, Limited
• 11. Dr. Reddy's Laboratories Ltd.
• 12. Genentech, Inc. by F. Hoffmann-La Roche AG
• 13. Lupin Ltd.
• 14. Natco Pharma Limited
• 15. Otsuka Pharmaceutical Co., Ltd.
• 16. Perrigo Company PLC
• 17. Pfizer Inc.
• 18. Sanofi S.A
• 19. Shenzhen Salubris Pharmaceuticals Co., Ltd.
• 20. Sun Pharmaceutical Industries, Inc.